Clinical Proof-Of-Concept
Based on its extensive human and pre-clinical safety and tolerability data, a unique mechanism of action and lack of known addictive properties, LAT8881 has significant potential to treat multiple neuropathic pain indications
Lateral aims to demonstrate efficacy of LAT 8881 in a human clinical proof-of-concept (POC) study within the next 12 months.
Safety
The substantial preclinical and human clinical data obtained with LAT8881 to date indicate a significant safety & tolerability profile. There have been no serious adverse events associated with administration of LAT8881 by IV or oral routes of delivery and the pattern of Adverse Events is indistinguishable from placebo.
